PPARγ

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 1000 patients randomized in the main and exploratory cohorts, including over 800 and 170 patients that have been treated for more than 24 and 72 weeks, respectively.This fifth DMC review confirms the good safety profile of lanifibranor. Daix (France), Long Island City (New York, United States), November 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the positive recommendation from the fifth scheduled meeting of the Data Monitoring Committee (“DMC”) to continue the NATiV3 Phase 3 clinical trial evaluating lanifibranor in patients with MASH without modification to the current trial protocol. The independent group of experts conducted its review based on the unblinded safety data from more than 1000 patients randomized in the main cohort and in the exploratory cohort. Among the more than 1000 patients whose data was reviewed, over 800 patients have been treated for more than 24 weeks, the treatment duration evaluated in the Phase 2b, NATIVE, study, and 177 patients have been treated for more than 72 weeks. The safety data was unblinded to the DMC but remains blinded with respect to the Company. The DMC review supports the continuation of the NATiV3 clinical trial without modification to the current trial protocol. This positive recommendation confirms the good safety and tolerability profile of lanifibranor. About lanifibranor Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and pre-clinical studies to date. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program. The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts Inventiva Pascaline ClercEVP, Strategy and Corporate Affairsmedia@inventivapharma.com +1 240 620 9175 Brunswick GroupTristan Roquet Montegon /Aude Lepreux /Matthieu BenoistMedia relationsinventiva@brunswickgroup.com +33 1 53 96 83 83 ICR HealthcarePatricia L. BankInvestor relationspatti.bank@westwicke.com +1 415 513-1284 Important Notice This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s pre-clinical programs and clinical trials, including design, protocol, duration, timing, recruitment costs, screening and enrollment for those trials, including the ongoing NATiV3 Phase 3 clinical trial with lanifibranor in MASH, including the possibility for patients to participate in those trials, the clinical development of and regulatory plans and pathway for lanifibranor, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the safety and tolerability profile and the potential therapeutic benefits of Inventiva’s product candidates, including lanifibranor, potential regulatory submissions, approvals, including potential accelerated approval in the United States and conditional approval Europe, and commercialization, Inventiva’s pipeline and preclinical and clinical development plans, the expected benefit of having received Breakthrough Therapy Designation, including its impact on the development and review timeline of Inventiva’s product candidates, the potential development of and regulatory pathway for odiparcil, and future activities, expectations, plans, growth and prospects of Inventiva and its partners. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”, “opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment or the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’s ability to obtain financing and to enter into potential transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners’ clinical trials may not support Inventiva's and its partners’ product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’s clinical trials, Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners’ control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva’s and its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2023 filed with the Autorité des Marchés Financiers on April 3, 2024 and the Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2024 for other risks and uncertainties affecting Inventiva, including those described under the caption “Risk Factors”, and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. Attachment Inventiva - PR - 5th DMC NATiV3 - EN - 10 30 2024

Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“ MASH ”), also known as non-alcoholic steatohepatitis (“ NASH ”), today announced that the results of the Phase 2, LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type-2-Diabetes (“ T2D ”) has been accepted as late breaker by the scientific committee of the upcoming 75 th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® 2024 being held November 15 to 19, 2024 in San Diego, California. Details of the presentation are as follow: Abstract title Combination therapy of lanifibranor with empagliflozin: metabolic improvement in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type-2 Diabetes (T2D) Publication number 5040 Type of presentation Poster presentation Authors Michelle Lai, Onno Holleboom, Lucile Dzen, Philippe Huot-Marchand, Jean-Louis Junien, Pierre Broqua, Louis Griffel, Sanjay Patel, Michael P Cooreman. Date and time Monday, November 18 th 8:00AM-5:00PM PST About lanifibranor Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH/NASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding pro to the favorable tolerability pro has been observed in clinical trials and pre-clinical studies to date. The FDA has granted Fast Track and Breakthrough Therapy designation to lanifibranor for the treatment of MASH/NASH. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program. The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts Inventiva Pascaline Clerc, PhD EVP, Strategy and Corporate Affairs media@inventivapharma.com +1 202 499 8937 Brunswick Group Tristan Roquet Montégon / Aude Lepreux / Julia Cailleteau Media relations inventiva@brunswickgroup.com +33 1 53 96 83 83 Westwicke, an ICR Company Patricia L. Bank Investor relations patti.bank@westwicke.com +1 415 513-1284 Important Notice This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s pre-clinical programs and clinical trials, including design, duration, timing, recruitment costs, screening and enrollment for those trials, including the ongoing NATiV3 Phase III clinical trial with lanifibranor in MASH/NASH and the LEGEND Phase II, Proof-of-Concept combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D, and the results and timing thereof and regulatory matters with respect thereto, , clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits including reduction in HbA1c, reduction in hepatic steatosis, the effect on liver enzymes (ALT and AST), insulin resistance (HOMA-IR), HDL, adiponectin, liver inflammation and fibrosis, and reduction in the VAT/SAT ratio, of lanifibranor alone and in combination with empagliflozin in patients with MASH/NASH and T2D, of Inventiva’s product candidates, including lanifibranor alone and in combination with empagliflozin, the effect of lanifibranor alone and in combination with empagliflozin on the weight of the patients receiving treatment, the tolerability and safety pro lanifibranor observed during trials, the potential of lanifibranor to address the specific metabolic unbalance in patients with T2D while also addressing steatosis and fibrosis, a hepatic consequence of insulin resistance, the estimated market size and patient population, potential regulatory submissions, approvals and commercialization, Inventiva’s pipeline and preclinical and clinical development plans, the potential development of and regulatory pathway for odiparcil, and future activities, expectations, plans, growth and prospects of Inventiva and its partners. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”, “opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management’s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva’s control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva cannot provide assurance on the impacts of the pause on enrolment or the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’s future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva’s and its partners’ clinical trials may not support Inventiva’s and its partners’ product candidate claims, Inventiva’s expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’s clinical trials, Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva’s and its partners’ control, Inventiva’s product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s and its partners’ business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva’s and its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2022 filed with the Autorité des Marchés Financiers on March 30, 2023 as amended on August 31, 2023, the Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2023, and the Half-Year Report for the six months ended June 30, 2023 on Form 6-K filed with the SEC on October 3, 2023, for other risks and uncertainties affecting Inventiva, including those described from time to time under the caption “Risk Factors”. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. Attachment Inventiva - PR - AASLD Abstract 2024 - EN - 10212024

前言 AIDD Pro 根据国内外各大网站以及人工智能药物设计主流新闻网站及公众号，从 AIDD会议、AIDD招聘，重大科研进展、行业动态、最新报告发布等角度，分析挖掘了每周人工智能辅助药物设计领域所发生的、对领域技术发展产生重大推动作用的事件，旨在帮助 AIDD领域研究人员和业内人士及时追踪最新科研动态、洞察前沿热点。如果您觉得符合以上要求的内容我们有遗漏或者更好建议，欢迎后台留言。 科研进展2024年10月18日【药物设计】ACS Omega | 利用CVAE生成模型增强跨多个治疗靶点的从头药物设计2024年10月18日【药物开发】ACS Nano | 应用细胞动力学的时空建模加速药物开发2024年10月18日【SARS-CoV-2】ACS Appl. Mater. Interfaces | 利用碳点研究硫醇功能在SARS-CoV-2病毒抑制中的意义2024年10月17日【抑制剂】J. Med. Chem. | 结构引导的构象限制导致高亲和力，选择性和细胞活性的基于四氢异喹啉的非共价Keap1-Nrf2抑制剂2024年10月17日【高通量筛选】Chem. Rev. | 利用高通量筛选实现遗传密码操作的新高度2024年10月16日【化学语言模型】J. Chem. Inf. Model. | 利用Product-of-Experts化学语言模型导航超大型虚拟化学空间 具体信息，请滑动下方文字 1.【药物设计】 药物发现是一个昂贵而耗时的过程，需要采用创新策略来提高从最初的药物识别到最终的市场批准等不同阶段的效率。深度学习（DL）的最新进展，特别是在新药物设计方面，显示出了希望。生成模型是深度学习算法的一个子类，通过探索广阔的化学空间，极大地加速了从头开始的药物设计过程。在这里，我们引入了一个为从头开始的分子设计任务量身定制的条件变分自编码器（CVAE）生成模型，利用smile和自拍作为分子表示。我们的计算框架通过独特性、有效性、新颖性、药物相似性定量估计（QED）和合成可及性（SA）等指标成功生成具有特定属性的分子。我们评估了我们的模型在产生能够结合三种治疗性分子靶点的新分子方面的功效：CDK2、PPARγ和DPP-IV。与最先进的框架进行比较表明，我们的模型能够在保持训练集分子中观察到的分子性质范围的同时实现更高的结构多样性。这个提出的模型是推进从头开始的分子设计能力的宝贵资源。 链接网址：https://pubs.acs.org/doi/10.1021/acsomega.4c08027 DOI：https://doi.org/10.1021/acsomega.4c08027 2.【药物开发】 细胞作为物理计算程序，利用输入信号来协调分子水平的蛋白质-蛋白质相互作用（PPIs），产生和响应力，最终形成所有的生理和病理生理行为。基因组编辑和靶向PPIs的分子药物对疾病的治疗有很大的希望。由于涉及广泛的空间和时间尺度，将基因和分子药物与蛋白质执行的细胞行为联系起来是一个关键但具有挑战性的问题。在生物学、化学、物理学和计算机科学的交叉领域，建立能够描述基因组编辑和分子药物干预的细胞动态行为的预测时空建模系统，将极大地加速制药的进步。在这里，我们回顾了细胞骨架蛋白在协调细胞行为中的机械作用，以及生物物理建模的重大进展，同时也解决了这些模型的局限性。然后，我们将生成式人工智能（AI）与时空多尺度生物物理建模相结合，提出了一种开发虚拟细胞的计算管道，可以模拟和评估药物和基因组编辑技术对各种细胞动态行为的治疗效果，具有广泛的生物医学应用前景。这种虚拟细胞建模系统可能会彻底改变现代生物医学工程，因为它将大部分艰苦的湿实验室工作转移到计算机模拟上，大大节省了时间，减轻了制药行业的经济负担。 链接网址：https://pubs.acs.org/doi/10.1021/acsnano.4c12599 DOI：https://doi.org/10.1021/acsnano.4c12599 3.【SARS-CoV-2】 虽然世界卫生组织宣布SARS-CoV-2突发公共卫生事件结束，但与冠状病毒相关的研究仍在进行中。截至2024年，通过目前的治疗和疫苗接种，COVID-19的严重程度已经降低。然而，个人仍然可能面临严重的并发症，这凸显了正在进行的针对当前和未来冠状病毒相关疾病的创新治疗研究的重要性。本研究探讨了病毒进入宿主细胞的机制以及目前使用巯基治疗COVID-19的证据。某些硫醇类药物是炎症过程的关键因素，既具有病毒抑制特性，又具有通过清除自由基来调节细胞氧化应激的潜力。在此，我们开发了生物相容性硫醇功能化碳点（CDs），并研究了硫醇数量与伪sars - cov -2抑制、活性氧（ROS）清除和抗炎反应之间的关系。自由基清除实验和ROS细胞实验表明，巯基化CDs是细胞氧化应激的有效还原剂和潜在调节剂。CDs还显示出良好的细胞活力和显著的抗病毒能力，抑制水平高达60.4%。此外，流式细胞术结果表明，在炎症环境中，巯基化CDs的存在促进了抗炎反应。总体而言，研究结果表明，硫醇的数量与实验中观察到的效率提高之间存在很强的相关性，这表明硫醇化CDs是预防和治疗COVID-19感染的有希望的候选者。 链接网址：https://pubs.acs.org/doi/10.1021/acsami.4c14482 DOI：https://doi.org/10.1021/acsami.4c14482 4.【抑制剂】 抑制Kelch-like ech -related protein 1 （Keap1）和核因子red - id 2相关因子2 （Nrf2）之间的蛋白质相互作用已被认为是治疗氧化应激相关疾病的一种有吸引力的方法。在这里，我们提出了一系列新的非共价Keap1-Nrf2抑制剂，这些抑制剂是通过先前通过基于片段的药物发现发现的基于芴酮的化合物的构象限制策略开发的。设计以x射线共晶结构为指导，随后的优化过程旨在提高亲和力、细胞活性和代谢稳定性。从非环化合物7 （Ki = 2.9 μM）中，获得了一系列新的基于四氢异喹啉的Keap1抑制剂，其结合亲和力（57,Ki = 13 nM）提高了223倍，代谢稳定性更好，细胞活性增强。此外，这些化合物在15个同源蛋白中对Keap1 Kelch结构域具有选择性。因此，我们证明了循环硬化在设计强效和更像药物的Keap1-Nrf2抑制剂中的效用。 链接网址：https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c01221 DOI：https://doi.org/10.1021/acs.jmedchem.4c01221 5.【高通量筛选】 蛋白质的化学和物理性质受到20种典型氨基酸的限制。遗传密码操作允许非规范氨基酸（ncAAs）的掺入，从而增强或改变蛋白质的功能。本文综述了将ncAAs引入生物合成蛋白的三种主要策略的进展，重点介绍了高通量筛选在这些进展中的作用。第一部分讨论了工程氨基酰基- tRNA合成酶（aaRSs）和tRNA，强调了新的选择方法如何提高包括ncAA结合效率和选择性在内的特性。第二部分探讨了提高蛋白质翻译机制的高通量技术，使替代遗传密码能够适应。这包括通过设计与翻译无关的细胞成分来增强ncAA结合的机会。最后一节重点介绍了用于高通量筛选含ncAA蛋白质的各种发现平台，展示了仅用标准氨基酸创建具有挑战性的创新结合配体和酶。这些进步带来了有希望的药物线索和生物催化剂。总体而言，通过高通量方法发现意外功能的能力显著影响ncAA的纳入及其应用。未来实验技术的创新，以及计算蛋白设计和机器学习的进步，将进一步提升这一领域的水平。 链接网址：https://pubs.acs.org/doi/10.1021/acs.chemrev.4c00329 DOI：https://doi.org/10.1021/acs.chemrev.4c00329 6.【化学语言模型】 超大的虚拟化学空间已经成为药物发现的宝贵资源，为数十亿种按需合成的化合物提供了高合成成功率。化学语言模型可以通过直接生成化合物来加速对这些广阔空间的探索。然而，现有的模型并不是为导航特定的虚拟化学空间而设计的，并且经常忽略了合成的可访问性。为了解决这一差距，我们引入了专家产品（PoE）化学语言模型，这是一种模块化和可扩展的方法，用于导航超大型虚拟化学空间。该方法通过将在目标空间上预训练的先验模型与使用外部属性特定数据集微调的专家和反专家模型相结合，允许在期望的化学空间内控制化合物的生成。我们证明PoE化学语言模型可以生成具有理想特性的化合物，例如那些有利于与多巴胺受体D2 （DRD2）对接的化合物，并且预计会穿过血脑屏障（BBB），同时确保大多数生成的化合物存在于目标化学空间内。我们的研究结果突出了化学语言模型在超大虚拟化学空间导航方面的潜力，我们预计这项研究将推动这一方向的进一步研究。源代码和数据可以在https://github.com/shuyana/poeclm上免费获得。 链接网址：https://pubs.acs.org/doi/10.1021/acs.jcim.4c01214 DOI：https://doi.org/10.1021/acs.jcim.4c01214 上下滚动查看更多 药企动态2024年10月18日【礼新医药】礼新医药完成3亿元C1轮融资2024年10月18日【阿斯利康】阿斯利康CTLA-4单抗在国内申报上市2024年10月17日【艾伯维】艾伯维24小时皮下输注疗法获FDA批准上市，治疗帕金森病2024年10月17日【默沙东】默沙东肺动脉高压新药国内申报上市2024年10月16日【丹诺医药】丹诺医药E轮融资逾3亿人民币！2024年10月16日【GSK】20年来首个！GSK first-in-class口服抗生素申报上市各动态具体信息，请滑动下方文字 1.【礼新医药】 2024年10月18日，礼新医药科技（上海）有限公司（以下简称“礼新医药”或”公司”）宣布，已于近日成功完成了3亿元C1轮融资，本轮融资由国内知名产业方中国生物制药领投，浦东创投、张江浩珩共同参与，老股东启明创投和上海生物医药基金跟投，中伦担任本轮融资的法律顾问。 链接网址请戳我 2.【阿斯利康】 10月18日，国家药品监督管理局药品审评中心（CDE）已受理阿斯利康的抗CTLA-4单抗Tremelimumab注射液的新药上市申请，这是该药首次在国内申报上市。 链接网址请戳我 3.【艾伯维】 10月17日，艾伯维宣布，FDA已批准VYALEV（ABBV-951）作为首款也是唯一一款基于左旋多巴的24小时皮下连续输注疗法，用于治疗晚期帕金森病（PD）成人患者的运动波动。 链接网址请戳我 4.【默沙东】 10月17日，国家药监局官网最新公示，默沙东申报的注射用sotatercept上市申请获得受理。Sotatercept是一款“first-in-class”新型激活素信号抑制剂类生物制剂。 链接网址请戳我 5.【丹诺医药】 10月16日，丹诺医药宣布完成逾3亿人民币E轮融资的首批交割。这轮融资由中山投控旗下中山创投和AMR Action Fund (AMR基金)共同领投，所获资金用于支持核心新药研发管线，包括治疗幽门螺杆菌感染新药候选物TNP-2198和治疗植入医疗器械感染新药候选物TNP-2092的后期临床试验和商业化。 链接网址请戳我 6.【GSK】10月16日，GSK宣布美国FDA已受理Gepotidacin的新药上市申请（NDA）并授予其优先审评资格，用于治疗单纯性尿路感染（uUTI）的女性成人患者（≥40kg）和青少年患者（≥12岁，≥40kg），PDUFA日期为2025年3月26日。 链接网址请戳我 上下滚动查看更多 会议信息 2024年10月24-25日 E药学苑举办ChemCon 2024第四届小分子药物创新开发论坛2025年1月9-10日 举办ICGT第八届细胞与基因治疗深度聚焦峰 各会议具体详情和参会方式，请滑动下方文字 ChemCon 2024第四届小分子药物创新开发论坛 主办方：E药学苑 会议时间：2024年10月24-25日 会议地点：南京 会议主旨：作为目前药物研发领域的主流，小分子药物具有许多优势和挑战。为推动研发和产业化的发展，促进行业内的学术交流与合作，邀请近百名知名专家学者分享他们在小分子创新药、改良型新药等领域的科研成果以及独到见解。 链接网址请戳我 ICGT第八届细胞与基因治疗深度聚焦峰 会议时间：2025年1月9-10日 会议地点：上海 会议主旨：共同探讨CGT产业链上中下游的关键环节，覆盖细胞免疫、眼科、罕见病和CMC热点议题，直面行业痛点，破解发展难点，共迎CGT产业的黄金十年。 链接网址请戳我 上下滚动查看更多 版权信息 本文内容均由小编收集于公开的各个网络平台，发布的目的仅为了方便大家一站式了解AIDD行业信息，并未对发布源头进行真实性验证。如您发现相关信息有任何版权侵扰或者信息错误，请及时联系AIDD Pro（请添加微信号sixiali_fox59）进行删改处理。 原创内容未经授权，禁止转载至其他平台。有问题可发邮件至sixiali@stonewise.cn 关注我，更多资讯早知道↓↓↓